International Clinical Trial: Efficacy and Safety of Gemcitabine-Cisplatin Plus Envafolimab as Neoadjuvant Therapy in Resectable Biliary Tract Malignancies at High Risk of Recurrence

Geneva, May 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123940) titled 'Efficacy and Safety of Gemcitabine-Cisplatin Plus Envafolimab as Neoadjuvant Therapy in Resectable Biliary Tract Malignancies at High Risk of Recurrence' on May 1.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Condition: Biliary Tract Malignancies

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-05-01

Target Sample Size: Neoadjuvant Therapy Group:34;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=321427

Disclaimer: Curated by HT S...